Trials / Terminated
TerminatedNCT00406575
Recombinant Human Relaxin for the Treatment of Decompensated CHF
A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF
Detailed description
Pilot clinical data suggest that recombinant human relaxin may be effective in treating patients with decompensated CHF. This study will randomize patients in blinded manner to one of two doses of intravenous relaxin or placebo. Serial evaluations will include cardiac and renal function, as well as safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication. |
| DRUG | Recombinant human relaxin (rhRlx) | Recombinant human relaxin (rhRlx) diluted for continuous IV infusion. |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2006-12-04
- Last updated
- 2014-05-07
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT00406575. Inclusion in this directory is not an endorsement.